Form 4 for GALT GALECTIN THERAPEUTICS INC
Accepted 2026-07-16 17:39:50 ET · period of report 2026-07-14 · accession 0001133416-26-000063 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-16 17:39 | 2026-07-14 | GALT | Jamil Khurram | Chief Medical Off | M - OptEx | $3.04 | +16.2K | 16.2K | New | +$49.4K |
| DT | 2026-07-16 17:39 | 2026-07-14 | GALT | Jamil Khurram | Chief Medical Off | S - Sale+OE | $5.13 | -16.2K | 0 | -100% | -$83.3K |
| DT | 2026-07-16 17:39 | 2026-07-14 | GALT | Jamil Khurram | Chief Medical Off | M - OptEx | $0.00 | -16.2K | 48.8K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-14 | M | A | 16,250 | $3.04 | 16,250 | D | — | — | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 |
| 2 | Common | Common Stock | 2026-07-14 | S | D | 16,250 | $5.13 | 0 | D | — | — | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 (F2) The shares were sold in multiple transactions at prices ranging from $5.00 to $5.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 3 | Derivative | Stock option (right to buy) | 2026-07-14 | M | D | 16,250 | $0.00 | 48,750 | D | $3.04 · 2026-06-30 to 2036-01-16 | 16,250 Common Stock | (F1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 (F3) The options vested at a rate of twenty five percent or 16,250 options on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027. |